• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • BioAsia 2023 to be held in February 24-26 in Telangana, India
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE
  • Event: Australia’s biggest week in biotech kicks off in Perth
  • $3 trillion growth reported for biotech sector in USA
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect”
  • Vaccination, Rising Deaths, And The False Narrative
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    July 26, 2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»COVAXIN Denial by FDA: is it Science or Purely Business

COVAXIN Denial by FDA: is it Science or Purely Business

0
By Biotech Express on June 14, 2021 Articles, Articles- Editorials, SARS- CoV2 & COVID-19 Updates

By Kamal Pratap Singh

Covaxin approval has been delayed after EUA rejection by FDA which will delay the use of COVAXIN in USA and other countries, instead the FDA has suggested for direct Biologics License Applications BLA or full use. Covaxin Approval from WHO is also pending next month i.e. July 2021.

International travel is also depending on vaccination status, many countries are now using it as a benchmark for allowing vaccinated foreign nationals to travel. Out of the three vaccines approved for use in India, only one—Covishield—features on the emergency use listing (EUL) of the World Health Organization (WHO).

To promote US manufacturing and suppress Indian manufacturers, earlier at the crucial times, USA banned raw material which was required in manufacturing.

Vaccine lobbying and politicization have been discussed and fairly understood several times in current pandemics of COVID-19. We have also covered news and article that discusses how many reasons other than science play role in decisive factors toward vaccination plannings.

We have seen that studies have been disapproved and even retracted from reputed journals like Lancet and NEJM of various treatments for COVID-19, seen how FDA and WHO’s roles in regulatory approval were criticized after retraction of these papers, seen how vaccine were approved and inoculated on mass scale even without proper approvals, all these just to get ahead in the race of vaccine nationalism and profiteering.

Will it lead to vaccine hesitancy
FDA actions in past and now lead us to think about the most important aspect i.e. vaccine hesitancy, the loss of trust in FDA approved products. I understand that two most important factors which are responsible to increase vaccine hesitancy among population are pharma profiteering and nationalism.

So what if America and Britain who declare themselves as superpowers becomes the largest supplier of vaccine and thus will attract huge money from the global communities that not only limited to national governments but extended to various organizations that are working in healthcare setting around the globe like WHO, GAVI, CEPI etc as seen in recent G7 summit. These organizations have multibillion dollar fund for the purpose of medical aids and these organizations gets funds from national governments of many countries.

Let us take the top three companies first, which are largest manufacturer of COVID-19 vaccines in current times
Pfizer/BioNTech
AstraZeneca
Moderna
Others are CanSino; Sinovac; Serum Institute of India, Johnson & Johnson;  Sputnik V; Sinopharm; Bharat Biotech etc.

If we see nationalism, AstraZeneca is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England and Pfizer is an American multinational pharmaceutical and biotechnology corporation headquartered in Manhattan, New York City both which first got EUA approval from US-FDA or WHO.

According to Baba Ramdev the owner of Patanjali Ayurveda, these western pharma companies work for profits only which they are eager to extend to populous countries like India. Baba Ramdev is not alone in this world with such blames, many other scientists and policy makers have made such claims.

Pharma profiteering to national products is apparent from current action of FDA which does not want an Indian vaccine in USA and thus declined application of BB which is providing lowest cost, most effective vaccine priced after considering humanitarian cause in pandemic and not for profits unlike many of the American and British companies that looks to work exclusively for money.

People vaccinated after Pfizer and Astrazeneca shots have shown side effects including some serious like blood clotting and anaphylaxis but the risks were diluted given the need of vaccine whereas Covaxinated subjects have not reported any side effects till now. The question also arise of phase 3 studies of BB’s Covaxin but 29 million people and 6 months of analysis have not proved as sufficient evidence toward its safety and efficacy. Still, FDA has asked for more COVAXIN trial data to be considered for approval. On the contrary, Covishield which is developed at University of Oxford, manufactured by British company AstraZeneca and sold by SII in India – enjoys approval in Europe as well as with the WHO.

COVAXIN of BB priced at Rs.150 for govt which is the lowest price one can offer. Considering others it is not making significant profit. It could have produced vaccine for world but BB has low manufacturing capacity which should have been increased to 50-100 folds given the opportunity of becoming world’s biggest biologics company from India.

Recently, BB said in a statement that “The supply price of Covaxin to the government of India at Rs 150 / dose, is a non-competitive price and clearly not sustainable in the long run. Hence a higher price in private markets is required to offset part of the costs,” it said in a statement.

SII had earlier given its per dose pricing of its ‘Covishield’ vaccine at ₹150 for the Central government, ₹400 for State governments and ₹600 for private hospitals while Bharat Biotech (which rolls out ‘Covaxin’) had quoted ₹150 for the Centre, ₹600 for State governments ₹1200 for private hospitals. This price difference has also created vaccine hesitancy to a large extent.

Now coming to the profits, in India only, AstraZeneca (British company) has sold 7 times the doses as compared to Covaxin at 213.6 million of Covishield against 29 million dose of Covaxin. And made profits to the tune of these numbers, since Covaxin has supplied mainly to govt. and because of delay of international approval it is not able to export to other countries which all lead to short supply of safest vaccine. Without being approved by the WHO or the FDA, Covaxin is unlikely to be accepted as a legitimate vaccine by many countries.

COVAXIN has also got the least funding from investors since the starting of its R&D programs whereas astrazeneca, Pfizer, SII have received huge amount for their vaccine discovery and manufacturing programs from institutions like national govt departments, philanthropic organizations etc.

Preferentially safe COVAXIN which is a whole inactivated virus vaccine is little costly to produce given inoculation and purification step that should be carried out in BSL-3 facility which itself is costly to built. Last week, the regulator in Brazil announced that Bharat Biotech would be allowed to import and administer Covaxin in the country, but with strict conditions of manufacturing, quality-control and delivery. It also restricted the import to 4 million doses, instead of the original 20 million.

On June 9, Bharat Biotech also announced that it would conduct phase 4 clinical trials of Covaxin, to assess the beleaguered vaccine’s real-world effectiveness. The company also added that data from the phase 3 trials would be available only in July, and not June as it had said earlier.

Thus far, India has administered 242.6 million vaccine doses – 213.6 million of Covishield and 29 million of Covaxin. As of June 9 morning, 14% of Indians have received at least one doses of either vaccine and 3.3% have received both doses.

It is also to be noted that recently American Pfizer has not been granted approval in India when it was willing to donate 5 billion doses to India, though it demanded indemnity too, after which SII had also demanded the same.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?

Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE

Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect”

Leave A Reply Cancel Reply

Current Issue – October 2022
Upcoming Event

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • BioAsia 2023 to be held in February 24-26 in Telangana, India January 10, 2023
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt November 10, 2022
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian? November 1, 2022
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE October 31, 2022
  • Event: Australia’s biggest week in biotech kicks off in Perth October 26, 2022
  • $3 trillion growth reported for biotech sector in USA October 25, 2022
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect” September 21, 2022
  • Vaccination, Rising Deaths, And The False Narrative September 20, 2022
  • Guestorial: Genome Mapping Techniques and its Application in Aquaculture September 19, 2022
  • Bombay HC Issues Notice To Bill Gates, Serum Institute, DGCI, Others Over Plea On Alleged ‘Vaccine Death’ September 5, 2022
  • Deaths due Covid-19 vaccines should be compensated by vaccine makers: Expert hope on Kerala HC remark August 21, 2022
  • Maker of Dolo-650, pandemic’s ‘magic pill’, faces income tax searches and PIL petitions August 20, 2022
  • Anthony Fauci, Controversial US Top-doc FINALLY, To Retire By Year-end August 20, 2022
  • SII’s Cervevac: The new DCGI approved vaccine without published clinical trial results August 20, 2022
  • Pitch your Start-up to National/International Venture Capitalists – first ever opportunity provided to Bio-Start-ups by FABA August 19, 2022
  • India’s Clinical Trial Registry might disappear soon and so the history of pharma record August 19, 2022
  • Nearly Half of Pregnant Women in Pfizer Trial Miscarried August 10, 2022
  • Researchers develop Cellulose shoes made by bacteria August 9, 2022
  • Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility August 5, 2022
  • CBI Arrests of CDSCO officials, a Biocon official & Intermediaries in an alleged bribery case exposed Corruption in Govt and Pharma sector July 27, 2022
  • We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO July 26, 2022
  • EVENT HIGHLIGHTS: Genome editing as a novel technology for sustainable development July 24, 2022
  • US Military Doctor Testifies under Oath That She Was ORDERED To ‘Cover up’ COVID Vaccine Injuries July 24, 2022
  • Climatic Effect on Marine Biodiversity and their impact on coral reefs July 23, 2022
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.